A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Poly ICLC (Primary) ; Romidepsin (Primary) ; Toll-like receptor 3 agonists
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
- 20 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 12 Dec 2018 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
- 12 Dec 2018 Planned End Date changed from 1 Jun 2018 to 1 Feb 2019.